RxDoctor Payments Data

Mary Nara, NP

Family · Las Vegas, NVNPI 1053369272

Payments from drug & device makers

$1,485in general payments, 2019–2025

Across 78 payments — averaging $19.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$343
  • Boehringer Ingelheim$275
  • Novo Nordisk$199
  • AstraZeneca$172
  • GSK$91
  • Lilly USA, LLC$84
  • plus $322 from 11 others

What the payments were for

  • Food & beverage$1,485100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,485 in reported general payments places this provider in the 75th percentile of 1,501 family providers in Nevada.

See all family providers in Nevada

Medicare billing

Part B allowed, 2024
$121,127
Medicare patients
324
Services billed
1,314

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide173$188,539
MounjaroTirzepatide113$115,493
EliquisApixaban98$114,819
JardianceEmpagliflozin78$105,007
XareltoRivaroxaban39$49,140
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$43,757
ProliaDenosumab20$34,302
LinzessLinaclotide28$26,376
WegovySemaglutide17$22,082
FarxigaDapagliflozin Propanediol12$18,114
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog33$15,291
EntrestoSacubitril/Valsartan13$10,423
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$10,210
Novolog FlexpenInsulin Aspart29$10,055
Arnuity ElliptaFluticasone Furoate14$6,166

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$199$210,621190 claims
PfizerEliquis, Prempro, Paxlovid$343$119,640134 claims
Lilly USA, LLCMounjaro$84$115,493113 claims
Boehringer IngelheimJardiance$275$105,00778 claims
GSKTrelegy Ellipta, Arnuity Ellipta, Incruse Ellipta$91$53,75656 claims
Johnson & JohnsonXarelto$13$49,14039 claims
AmgenProlia$21$34,30220 claims
AstraZenecaFarxiga, Symbicort$172$22,39925 claims
NovartisEntresto$20$10,42313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,501 family providers in Nevada.

Other family in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →